Article Text

other Versions

PDF
What effects might anti-TNFá therapy be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF[alpha] in cardiovascular pathophysiology.
  1. W G Dixon (will.dixon{at}manchester.ac.uk)
  1. arc Epidemiology Unit, University of Manchester, United Kingdom
    1. D PM Symmons (deborah.symmons{at}manchester.ac.uk)
    1. arc Epidemiology Unit, University of Manchester, United Kingdom

      Abstract

      Patients with rheumatoid arthritis (RA) have an increased burden of atherosclerotic cardiovascular disease which cannot be explained by an increased prevalence of traditional cardiovascular risk factors alone. Atherosclerosis is now being viewed as an inflammatory condition and the cumulative inflammation experienced in RA may contribute to accelerated atherosclerosis.

      It has been hypothesised that anti-TNFá therapy in RA may reduce both intra-articular inflammation and the inflammation associated with atherosclerosis. Thus TNFá blockade may reduce the cardiovascular morbidity and mortality associated with RA. This review examines the pathophysiological role of TNFá in atherosclerosis and the evidence to date that anti- TNFá therapy modifies this process in RA.

      • anti-TNF[alpha] therapy
      • cardiovascular co-morbidity
      • rheumatoid arthritis

      Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.